Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Viking Therapeutics stock (VKTX)

Buy Viking Therapeutics stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Viking Therapeutics is a biotechnology business based in the US. Viking Therapeutics shares (VKTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $73.35 – an increase of 21.46% over the previous week. Viking Therapeutics employs 27 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Viking Therapeutics stock

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • Complimentary access to a financial planner and automated investing

How to buy Viking Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – VKTX. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Viking Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a no-advisory-fee robo-advisor and complimentary access to financial planners.
Robinhood
Finder Score: 4.5 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Viking Therapeutics stock price (NASDAQ: VKTX)

Use our graph to track the performance of VKTX stocks over time.

Viking Therapeutics shares at a glance

Information last updated 2024-10-25.
Latest market close$73.35
52-week range$9.25 - $99.41
50-day moving average $63.10
200-day moving average $58.25
Wall St. target price$113.91
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-0.94

Is it a good time to buy Viking Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Viking Therapeutics price performance over time

Historical closes compared with the close of $74.52 from 2024-10-28

1 week (2024-10-22) 20.14%
1 month (2024-09-30) 17.71%
3 months (2024-07-30) 31.85%
6 months (2024-04-30) -6.36%
1 year (2023-10-30) 677.87%
2 years (2022-10-28) 1,691.35%
3 years (2021-10-29) 1,180.41%
5 years (2019-10-30) 1,042.94%

Viking Therapeutics financials

Gross profit TTM $0
Return on assets TTM -12.68%
Return on equity TTM -15.5%
Profit margin 0%
Book value $8.18
Market Capitalization $8.2 billion

TTM: trailing 12 months

Viking Therapeutics share dividends

We're not expecting Viking Therapeutics to pay a dividend over the next 12 months.

Viking Therapeutics share price volatility

Over the last 12 months, Viking Therapeutics's shares have ranged in value from as little as $9.25 up to $99.41. A popular way to gauge a stock's volatility is its "beta".

VKTX.US volatility(beta: 1)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Viking Therapeutics's is 0.998. This would suggest that Viking Therapeutics's shares are less volatile than average (for this exchange).

Viking Therapeutics overview

Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. .

Frequently asked questions

What percentage of Viking Therapeutics is owned by insiders or institutions?
Currently 6.033% of Viking Therapeutics shares are held by insiders and 75.293% by institutions.
How many people work for Viking Therapeutics?
Latest data suggests 27 work at Viking Therapeutics.
When does the fiscal year end for Viking Therapeutics?
Viking Therapeutics's fiscal year ends in December.
Where is Viking Therapeutics based?
Viking Therapeutics's address is: 9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121
What is Viking Therapeutics's ISIN number?
Viking Therapeutics's international securities identification number is: US92686J1060
What is Viking Therapeutics's CUSIP number?
Viking Therapeutics's Committee on Uniform Securities Identification Procedures number is: 92686J106

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site